These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 24093499

  • 1. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
    Tella SH, Gallagher JC.
    Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
    [Abstract] [Full Text] [Related]

  • 2. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV, Pickar JH, Racketa J, Mirkin S.
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [Abstract] [Full Text] [Related]

  • 3. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S, Komm BS.
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [Abstract] [Full Text] [Related]

  • 4. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss.
    Komm BS, Mirkin S, Jenkins SN.
    Steroids; 2014 Nov; 90():71-81. PubMed ID: 24929044
    [Abstract] [Full Text] [Related]

  • 5. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
    Pinkerton JV, Stovall DW.
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
    [Abstract] [Full Text] [Related]

  • 6. Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).
    Lindsay R.
    Osteoporos Int; 2011 Feb; 22(2):447-51. PubMed ID: 21069294
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
    Umland EM, Karel L, Santoro N.
    Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ, Gillespie JA.
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms.
    Stovall DW.
    Curr Opin Investig Drugs; 2010 Apr; 11(4):464-71. PubMed ID: 20336595
    [Abstract] [Full Text] [Related]

  • 17. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH.
    Menopause; 2009 Apr; 16(6):1116-24. PubMed ID: 19546826
    [Abstract] [Full Text] [Related]

  • 18. Treating menopausal symptoms with a tissue-selective estrogen complex.
    Levine JP.
    Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
    [Abstract] [Full Text] [Related]

  • 19. Selective estrogen modulators in menopause.
    Gambacciani M.
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.